檢索結果 - Jean‐Michel Vernier
- Showing 1 - 3 results of 3
-
1
RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer 由 Cory Iverson, Gary Larson, Chon Lai, Li‐Tain Yeh, Claudia Dadson, Paul Weingarten, T.C. Appleby, Todd Vo, Andreas Maderna, Jean‐Michel Vernier, Robert Hamatake, Jeffrey N. Miner, Barry Quart
出版 2009Artigo -
2
Group II mGlu Receptor Activation Suppresses Norepinephrine Release in the Ventral Hippocampus and Locomotor Responses to Acute Ketamine Challenge 由 Daniel S. Lorrain, Hervé Schaffhauser, Una C. Campbell, Christopher Baccei, Lucia Correa, Blake A. Rowe, Dana E. Rodriguez, Jeffery J. Anderson, Mark A. Varney, Anthony B. Pinkerton, Jean‐Michel Vernier, Linda J. Bristow
出版 2003Artigo -
3
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications 由 Elena Ardini, Maria Menichincheri, Patrizia Banfi, Roberta Bosotti, Cristina Ponti, Romana Pulci, Dario Ballinari, Marina Ciomei, Gemma Texidó, Anna Degrassi, Nilla Avanzi, Nadia Amboldi, Maria Beatrice Saccardo, Daniele Casero, Paolo Orsini, Tiziano Bandiera, Luca Mologni, David W. Anderson, Wei Ge, Jason Harris, Jean‐Michel Vernier, Gang Li, Eduard Felder, Daniele Donati, Antonella Isacchi, Enrico Pesenti, Paola Magnaghi, Arturo Galvani
出版 2016Artigo
相關主題
Internal medicine
Medicine
Biochemistry
Biology
Cancer
Cancer research
Chemistry
Pharmacology
Receptor
ALK inhibitor
Adenocarcinoma
Agonist
Alectinib
Allosteric regulation
Anaplastic lymphoma kinase
Biotechnology
Ceritinib
Colorectal cancer
Crizotinib
Dopamine
Enzyme
Glutamate receptor
Hippocampus
In vitro
In vivo
Inhibitory postsynaptic potential
Ketamine
Kinase
Lung cancer
MAPK/ERK pathway